Abstract Number: 130 • 2020 Pediatric Rheumatology Symposium
Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is related to disease severity, morbidity, and mortality in juvenile systemic lupus erythematosus (jSLE). Cluster analysis emerged to identify autoantibody profiles…Abstract Number: 66 • 2019 ACR/ARP Annual Meeting
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…Abstract Number: 2556 • 2019 ACR/ARP Annual Meeting
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for…Abstract Number: 72 • 2019 ACR/ARP Annual Meeting
The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease
Background/Purpose: Lupus nephritis is a complex and heterogeneous disease characterized by infiltrating immune cells in damaged kidney tissue. While mouse models have enabled mechanistic studies…Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…Abstract Number: 653 • 2019 ACR/ARP Annual Meeting
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
Background/Purpose: Elderly-onset SLE is recognized to be benign disease entity with a favorable nature course. Although late-onset lupus nephritis (LN), long interval between onset of…Abstract Number: 1733 • 2019 ACR/ARP Annual Meeting
Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort
Background/Purpose: Compared to adult-onset disease, pediatric-onset SLE (p-SLE) has more severe renal involvement. There are no population-based, long-term follow-up studies of pediatric lupus nephritis (LN)…Abstract Number: 2568 • 2019 ACR/ARP Annual Meeting
Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Background/Purpose: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive…Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…Abstract Number: 1735 • 2019 ACR/ARP Annual Meeting
Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset systemic lupus erythematosus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 37
- Next Page »